Shots:
- Sun Pharma has reported Unloxcyt (cosibelimab-ipdl) is now available in the US for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not eligible for curative surgery or radiation
- Approval of label update was based on long-term pivotal CK-301-101 data, showing improved ORR, including higher CR, and DoR without new safety signals. At least 50% of pts achieved an OR(complete or partial), including mCSCC 13% pts and laCSCC 26% pts who achieved complete response. 71% achieved disease control, and mDoR was not reached in mCSCC or laCSCC
- Unloxcyt is a human, anti-PD-L1 IgG1 mAb which blocks the interaction between PD-L1 & T cell receptors (PD-1 & B7.1) producing an anti-tumor immune response
Ref: Sun Pharma | Image: Sun Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
